001     166504
005     20250730152255.0
024 7 _ |a 10.1016/j.bmc.2013.09.029
|2 doi
024 7 _ |a 1464-3391
|2 ISSN
024 7 _ |a 0968-0896
|2 ISSN
024 7 _ |a WOS:000325759800009
|2 WOS
024 7 _ |a pmid:24103428
|2 pmid
024 7 _ |a openalex:W2048738240
|2 openalex
037 _ _ |a DESY-2014-01386
082 _ _ |a 540
100 1 _ |a Čapkauskaitė, Edita
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Benzenesulfonamides with pyrimidine moiety as inhibitors of human carbonic anhydrases I, II, VI, VII, XII, and XIII
260 _ _ |a Amsterdam [u.a.]
|c 2013
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1531338246_17593
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a © Elsevier Ltd. ; Post referee fulltext in progress; Embargo 12 months from publication
|3 POF3_Assignment on 2016-02-10
520 _ _ |a Two groups of benzenesulfonamide derivatives, bearing pyrimidine moieties, were designed and synthesized as inhibitors of carbonic anhydrases (CA). Their binding affinities to six recombinant human CA isoforms I, II, VI, VII, XII, and XIII were determined by the thermal shift assay (TSA). The binding of several inhibitors was measured by isothermal titration calorimetry (ITC). Direct demonstration of compound inhibition was achieved by determining the inhibition constant by stopped-flow CO2 hydration assay. The most potent compounds demonstrated selectivity towards isoform I and affinities of 0.5nM. The crystal structures of selected compounds in complex with CA II, XII, and XIII were determined to atomic resolution. Compounds described here were compared with previously published pyrimidinebenzenesulfonamides.(1) Systematic structure-activity analysis of 40 compound interactions with six isoforms yields clues for the design of compounds with greater affinities and selectivities towards target CA isoforms.
536 _ _ |0 G:(DE-H253)POF2-P14-20130405
|f POF II
|x 0
|c POF2-54G14
|a PETRA Beamline P14 (POF2-54G14)
536 _ _ |0 G:(DE-H253)POF2-K1.1-20130405
|f POF II
|x 1
|c POF2-54G13
|a DORIS Beamline K1.1 (POF2-54G13)
588 _ _ |a Dataset connected to CrossRef, bib-pubdb1.desy.de
693 _ _ |a PETRA III
|f PETRA Beamline P14
|1 EXP:(DE-H253)PETRAIII-20150101
|0 EXP:(DE-H253)P-P14-20150101
|6 EXP:(DE-H253)P-P14-20150101
|x 0
693 _ _ |a DORIS III
|f DORIS Beamline K1.1
|1 EXP:(DE-H253)DORISIII-20150101
|0 EXP:(DE-H253)D-K1.1-20150101
|6 EXP:(DE-H253)D-K1.1-20150101
|x 1
700 1 _ |a Zubrienė, Asta
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Smirnov, Alexey
|0 P:(DE-H253)PIP1018767
|b 2
700 1 _ |a Torresan, Jolanta
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Kišonaitė, Miglė
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Kazokaitė, Justina
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Gylytė, Joana
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Michailovienė, Vilma
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Jogaitė, Vaida
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Manakova, Elena
|0 P:(DE-H253)PIP1017370
|b 9
700 1 _ |a Gražulis, Saulius
|0 P:(DE-H253)PIP1018629
|b 10
700 1 _ |a Tumkevičius, Sigitas
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Matulis, Daumantas
|0 P:(DE-HGF)0
|b 12
|e Corresponding author
773 _ _ |a 10.1016/j.bmc.2013.09.029
|g Vol. 21, no. 22, p. 6937 - 6947
|0 PERI:(DE-600)1501507-5
|n 22
|p 6937 - 6947
|t Bioorganic & medicinal chemistry
|v 21
|y 2013
|x 0968-0896
856 4 _ |u https://bib-pubdb1.desy.de/record/166504/files/DESY-2014-01386.pdf
|y Restricted
856 4 _ |u https://bib-pubdb1.desy.de/record/166504/files/DESY-2014-01386.jpg?subformat=icon-1440
|x icon-1440
|y Restricted
856 4 _ |u https://bib-pubdb1.desy.de/record/166504/files/DESY-2014-01386.jpg?subformat=icon-180
|x icon-180
|y Restricted
856 4 _ |u https://bib-pubdb1.desy.de/record/166504/files/DESY-2014-01386.jpg?subformat=icon-640
|x icon-640
|y Restricted
909 C O |p VDB
|o oai:bib-pubdb1.desy.de:166504
910 1 _ |a Externes Institut
|0 I:(DE-HGF)0
|k Extern
|b 2
|6 P:(DE-H253)PIP1018767
910 1 _ |a Externes Institut
|0 I:(DE-HGF)0
|k Extern
|b 9
|6 P:(DE-H253)PIP1017370
910 1 _ |a Externes Institut
|0 I:(DE-HGF)0
|k Extern
|b 10
|6 P:(DE-H253)PIP1018629
913 2 _ |a DE-HGF
|b Forschungsbereich Materie
|l Von Materie zu Materialien und Leben
|1 G:(DE-HGF)POF3-620
|0 G:(DE-HGF)POF3-622
|2 G:(DE-HGF)POF3-600
|v Facility topic: Research on Matter with Brilliant Light Sources
|9 G:(DE-HGF)POF3-6G3
|x 0
913 1 _ |b Struktur der Materie
|1 G:(DE-HGF)POF2-540
|0 G:(DE-HGF)POF2-54G14
|2 G:(DE-HGF)POF2-500
|v PETRA III
|9 G:(DE-H253)POF2-P14-20130405
|x 0
|a DE-H253
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF2
|l Forschung mit Photonen, Neutronen, Ionen
913 1 _ |b Struktur der Materie
|1 G:(DE-HGF)POF2-540
|0 G:(DE-HGF)POF2-54G13
|2 G:(DE-HGF)POF2-500
|v DORIS III
|9 G:(DE-H253)POF2-K1.1-20130405
|x 1
|a DE-H253
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF2
|l Forschung mit Photonen, Neutronen, Ionen
914 1 _ |y 2013
915 _ _ |a Peer review unknown
|0 StatID:(DE-HGF)0040
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
920 1 _ |0 I:(DE-H253)EMBL-User-20120814
|k EMBL-User
|l EMBL-User
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-H253)EMBL-User-20120814
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21